One could argue we are in the beginning of the harsh gap between the two eras. In 2012 the pharma industry contracted for the first time ever. Many industry ins

One could argue we are in the beginning of the harsh gap between the two eras. In 2012 the pharma industry contracted for the first time ever. Many industry insiders argue the traditional r&d model is broken There is an emerging wave of new therapeutic modalities (cell therapy, gene therapy, microbiome therapy, bioelecrronic medicine, etc) but it isn't clear if these will be as significant as antibodies were in the 1980s http://blogs.sciencemag.org/pipeline/archives/2017/11/28/a-grim-future-here-are-the-numbers http://blogs.sciencemag.org/pipeline/archives/2017/11/28/a-g...